<DOC>
	<DOCNO>NCT00906841</DOCNO>
	<brief_summary>Phase II , multi-centric , open-label , study . Disseminated diffuse large B-cell lymphoma patient older 60 : evaluation fractionate radio-immunotherapy 90Y-DOTA-hLL2 consolidation therapy first line chemotherapy .</brief_summary>
	<brief_title>Study 90Y-DOTA-hLL2 Consolidation Therapy After R-CHOP Patients With Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Initial treatment : 6 course CHOP-R 14 evaluation response C4 ( observation change progression time get patient study ) . Consolidation : fractionate RIT ( 8 week end R-CHOP : 2 injection 15 mCi/m2 90Y-DOTA-hLL2 hLL2 day 1 day 8 ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Age &gt; 60 &lt; 80 year Non eligible stem cell transplantation CD20 diffuse large Bcell lymphoma accord WHO classification Bulky stage I II &gt; ou =7 cm stage III IV Performance status 0 2 Creatinine clearance &gt; ou = 50 ml/min ( Cockroft formula ) . Serum bilirubin &lt; ou =30 mmol/l Leucocytes &gt; ou =3 G/l , granulocytes &gt; ou = 1,5 G/l , platelets &gt; ou= 100 G/L . HIV negative Written inform consent Age &lt; 60 year &gt; 80 year Other type lymphomas except CD20+ diffuse large Bcell lymphoma accord WHO classification Histologic transformation low grade lymphoma ( Involvement bone marrow small Bcell lymphoma lead exclusion patient ) Primary lymphoma central nervous system transform gastro intestinal MALT lymphoma Meningeal involvement Bone marrow involvement &gt; 25 % RCHOP Aggressive posttransplantation lymphoma Absence CD20 expression tumor cell Non bulky stage I et II HIV positive Active Hepatitis B C Left ventricular ejection fraction &lt; 50 % . Contraindication RCHOP treatment Previous concurrent second malignancy except adequately treat basal cell carcinoma skin , curatively treat situ carcinoma cervix , curatively treat solid cancer , evidence disease least 5 year Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Participation time another study investigational drug use Absence write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Disseminated diffuse large B-cell lymphoma</keyword>
	<keyword>first line treatment</keyword>
	<keyword>R CHOP</keyword>
	<keyword>90Y-DOTA-hLL2</keyword>
	<keyword>Patients older 60 year</keyword>
</DOC>